All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Mosunetuzumab receives European Commission approval for the treatment of relapsed or refractory follicular lymphoma

Jun 17, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in follicular lymphoma

On June 8, 2022, it was announced that the European Commission (EC) has granted approval for the use of mosunetuzumab, a CD20 × CD3 T-cell engaging bispecific antibody, for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received ≥2 lines of systemic therapy. The approval is based on data obtained from the phase I/II GO29781 trial (NCT02500407),1 previously reported on the Lymphoma Hub.

Efficacy1

  • 80% overall response rate
  • 60% complete response rate
  • Median duration of response was 22.8 months

Safety1

  • Overall, 39% of patients experienced any-grade cytokine release syndrome, with 14% being Grade 2.
  • Most common adverse events were neutropenia, pyrexia, hypophosphatemia, and headache.
  • Initial treatment dose was administered without mandatory hospitalization.

  1.  European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma. https://www.roche.com/media/releases/med-cor-2022-06-08. Published June 8, 2022. Accessed June 16, 2022.

Share: